# Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease

> **NCT07671222** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Instituto de Oftalmología Fundación Conde de Valenciana** · enrollment: 38 (estimated)

## Conditions studied

- Sjogren Syndrome
- Sjogren Syndrome With Keratoconjunctivitis
- Dry Eye Disease (DED)

## Interventions

- **DRUG:** Infliximab 0.1%
- **DRUG:** Loteprednol

## Key facts

- **NCT ID:** NCT07671222
- **Lead sponsor:** Instituto de Oftalmología Fundación Conde de Valenciana
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2028-03
- **Final completion:** 2028-03
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07671222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07671222, "Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07671222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*